Study of the Link Between Complement Activation and IgA Nephropathy Severity
Recruiting now
Conditions studied: IgA Nephropathy Severity in Kidney Transplantation
In brief
ICONE study (IgA Complement and NEphropathy is a prospective monocentric observational study. The main objective is to evaluate the relevance of complement activation as a biomarker of disease severity and progression in patients with a biopsy proven IgAN.
Key facts
- Study ID
- NCT05234463
- Run by
- University Hospital, Strasbourg, France
- People needed
- 400
- Starts
- 2022-05-09
- Expected to finish
- 2027-05-01
- Last updated by the study team
- 2025-08-03
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Adult patients, male or female, with a biopsy proven IgA nephropathy.
- Primitive and secondary forms can be included
- Regardless of the date of diagnosis and the level of kidney function
- With or without past of kidney transplantation
- Followed in the Nephrology Department, Strasbourg University Hospital
- Signed informed consent
You may not qualify if…
- Active or recent infectious or inflammatory syndrome (<2 months), recent vaccination (<2 months), ongoing acute humoral rejection treatment, treatment with plasma exchanges (<2 months), current treatment with complement inhibitors
- Impossibility of giving informed information (emergency situation, difficulties in understanding, etc.)
- Subject under safeguard of justice, guardianship or curatorship
Where it is running
- Service de néphrologie — Strasbourg, France (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.